- (1) The study must fit within the responsibilities of the Department for health and welfare.
- (2) De-identified prescriber, patient and pharmacy data will meet the research needs.
(3) The research facility designee must provide:
- (a) written assurances that the studies are not conducted for and will not be used for profit or commercial gain;
- (b) written assurances that the designee shall protect the information as a business associate of the Department of Health and Human Services; and
- (c) documentation of an Institutional Review Board approval.
KEY: prescription drug database, controlled substances, substance abuse database
Date of Last Change: November 5, 2023
Notice of Continuation: February 20, 2024
Authorizing, and Implemented or Interpreted Law: 58-37f-301(2)(f)